olmesartan has been researched along with quinidine in 5 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (quinidine) | Trials (quinidine) | Recent Studies (post-2010) (quinidine) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 6,608 | 387 | 594 |
| Protein | Taxonomy | olmesartan (IC50) | quinidine (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 6.4 | |
| Cholinesterase | Homo sapiens (human) | 1.23 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 3.32 | |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | 2.8 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.3532 | |
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | 7.3 | |
| Cholinesterase | Equus caballus (horse) | 7.37 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 6.4 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.7882 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 6.4 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 6.4 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 6.9 | |
| Potassium voltage-gated channel subfamily D member 2 | Rattus norvegicus (Norway rat) | 2.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
1 review(s) available for olmesartan and quinidine
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
4 other study(ies) available for olmesartan and quinidine
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |